Tumorigenesis of colorectal cancer cells (CT26, red) were significantly reduced...
Tumorigenesis of colorectal cancer cells (CT26, red) were significantly reduced in mice liver tissue lacking IL-6 (Il6-/-), suggesting IL-6’s supportive function on metastasis.

Image source: Toyoshima Y. et al., Cancer Immunology Research 2019

Promising treatment target

"Partner-in-crime" of colorectal cancer discovered

A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target, researchers from Hokkaido University discovered.

Colorectal cancer patients with an immune system-regulating protein called interleukin 6 (IL-6) are more likely to have recurring tumors that can also spread to the liver, according to research published in the journal Cancer Immunology Research. The Hokkaido University investigations into the protein’s role in liver metastasis could help improve colorectal cancer treatment options. Colorectal cancer is the second most common cancer in women and third most common in men. The spreading of this cancer to other organs, most often to the liver, significantly reduces patient survival.

portrait of hidemitsu kitamura
Hidemitsu Kitamura of the Hokkaido University’s Institute for Genetic Medicine.
Source: Hokkaido University

One cancer treatment approach is immune therapy, which stimulates a person’s own immune system to attack tumor sites. However, its effectiveness varies with different cancers and in different people. This suggests that several different mechanisms are working at the same time to suppress the immune systems of those with cancer. Scientists are seeking ways to improve the effectiveness of immune therapy for patients.

Immunologist Hidemitsu Kitamura and colleagues at Japan’s Hokkaido University had previously found IL-6 expression plays a role in suppressing immune response in tumor tissues. They wanted to see if it also helps spread colorectal cancer to the liver. To do this, they used two groups of mice, one in which IL-6 expression was turned off and the other with IL-6 expression turned on. Both groups were inoculated with colorectal cancer cells. They assessed cancer levels in the liver, as well as the effects of IL-6 on different types of immune cells. They also analyzed IL-6 expression in human colorectal cancer patients.

“We hope that targeting IL-6 will be an effective approach to reduce the spread of cancer and improve survival in colorectal cancer patients. This approach could be combined with other immune therapy strategies, such as the one targeting PD-L1, to augment their effects on colorectal cancer in the future,” says Hidemitsu Kitamura.


Source: Hokkaido University

21.02.2020

Read all latest stories

Related articles

Photo

Cause for colorectal carcinoma

Loss of protein can drive intestinal cancer

An international team of researchers from the University of Zurich, the University Hospital Zurich, Heidelberg and Glasgow has identified a novel function for the cell death regulating protein MCL1:…

Photo

Gastroenterology

Crohn's disease linked to increased risk of colorectal cancer

Researchers from Karolinska Institutet, Örebro University and Aarhus University, Denmark, have published the largest study to date on the risk of colorectal cancer in Crohn's disease. The article is…

Photo

Major global study reveals

Colorectal, pancreatic cancer rates up 10% in last 30 years

The results of a major study across 195 countries, presented at UEG Week Barcelona 2019, indicate that global death rates for pancreatic cancer and incidence rates for colorectal cancer both…

Related products

Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH